DOCSLIB.ORG

National Drugs and Poisons Schedule Committee

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Drugs and Poisons Schedule Committee National Drugs and Poisons Schedule Committee Record of the Reasons 36th Meeting 15-17 October 2002 The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Secretariat is moving towards including the edited minutes as the Record of the Reasons. With this document, we have included edited extracts relating to scheduling considerations for OTC medicines, domestic poisons and certain matters related to pesticides. The Secretariat is hopeful of including the edited minutes for all sectors following consultation with the respective industry bodies. National Drugs and Poisons Schedule Committee Record of the Reasons for Meeting 36 - October 2002 i TABLE OF CONTENTS GLOSSARY..........................................................................................................................................IV 2. PROPOSED CHANGES/ADDITIONS TO PARTS 1 TO 3 AND PART 5 OF THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS............................. 1 2.1 SUSDP, PART 1......................................................................................................................... 1 2.1.1 Definition in Part 1 of the SUSDP for “aqueous preparations” .......................................... 1 2.2 SUSDP, PART 2......................................................................................................................... 1 2.2.1 Variation of Requirement for Clause 7(1)(d)....................................................................... 1 2.4 SUSDP, PART 5 .......................................................................................................................... 2 2.4.1 Pesticides Listed in Appendix J .......................................................................................... 2 2.4.2 Appendix B ........................................................................................................................ 4 AGRICULTURAL/VETERINARY, INDUSTRIAL AND DOMESTIC CHEMICALS........................... 14 4. OTHER OUTSTANDING MATTERS FROM PREVIOUS MEETINGS ................................ 14 4.1 PESTICIDES IN PAINT.................................................................................................................. 14 4.2 APPENDIX E, PART 1, STATEMENT A – NZ PIC NO. ................................................................... 15 4.3 APPENDIX E, PART 2 - PHENOLS ................................................................................................ 16 4.4 CHLORINATING COMPOUNDS ..................................................................................................... 18 4.5 LITHIUM IN PIGMENTS ............................................................................................................... 23 4.6 INSULIN-LIKE GROWTH FACTORS............................................................................................... 24 6. MATTERS REFERRED BY THE NATIONAL REGISTRATION AUTHORITY FOR AGRICULTURAL AND VETERINARY CHEMICALS ................................................................... 25 6.1 DIRECT-FED MICROBIALS .......................................................................................................... 25 6.2 FLUMIOXAZIN............................................................................................................................ 27 6.3 BIFENAZATE.............................................................................................................................. 27 6.4 TETRACONAZOLE ...................................................................................................................... 27 6.5 CLOTHIANIDIN........................................................................................................................... 28 6.6 MOXIDECTIN ............................................................................................................................. 28 6.7 MAGNESIUM FLUOROSILICATE/SULFUR/ROTENONE.................................................................... 28 6.8 EXTRACT OF LEMON EUCALYPTUS ............................................................................................. 29 6.9 CARBARYL ................................................................................................................................30 6.10 DIQUAT ................................................................................................................................30 6.11 CODLING MOTH GRANULOSIS VIRUS ..................................................................................... 31 8. ANTIBIOTICS FOR CONSIDERATION FOLLOWING RECOMMENDATIONS OF THE JOINT EXPERT TECHNICAL ADVISORY COMMITTEE ON ANTIBIOTIC RESISTANCE (JETACAR) .......................................................................................................................................... 31 8.1 VIRGINIAMYCIN......................................................................................................................... 31 8.2 ANTIBIOTICS IN PREPARATIONS FOR INTRA-MAMMARY INFUSION IN ANIMALS ............................ 31 8.3 FUTURE REVIEWS/TIMETABLE ................................................................................................... 33 8.3.1 Antibiotic Substances Already Gazetted For Review ......................................................... 35 8.3.2 Substances To Be Included In The Post-NDPSC 36 Meeting Gazette Notice...................... 36 PHARMACEUTICALS ....................................................................................................................... 38 13. OTHER OUTSTANDING MATTERS FROM PREVIOUS MEETINGS ................................ 38 13.1 MELIA AZEDARACH .............................................................................................................. 38 National Drugs and Poisons Schedule Committee Record of the Reasons for Meeting 36 - October 2002 ii 13.2 AZADIRACHTA INDICA (NEEM).............................................................................................. 41 13.3 FLUVOXAMINE AND VENLAFAXINE........................................................................................ 49 13.5 PSEUDOEPHEDRINE ............................................................................................................... 51 13.6 SODIUM PICOSULFATE AND MACROGOL 3350 ........................................................................ 56 13.7 POLYACRYLAMIDE................................................................................................................ 58 13.8 RANITIDINE, CIMETIDINE, FAMOTIDINE AND NIZATIDINE ....................................................... 59 13.9 HYDROCORTISONE/CLOTRIMAZOLE ....................................................................................... 62 14. PROPOSED CHANGES/ADDITIONS TO THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS...................................................................................... 64 14.1 SUSDP, PART 4.................................................................................................................... 64 14.1.1 Flurbiprofen .................................................................................................................... 64 14.1.2 Acetylcysteine .................................................................................................................. 66 14.1.3 Macrogol 3350, Sodium Phosphate and Sodium Picosulfate ............................................. 69 14.1.4 Budesonide ...................................................................................................................... 70 14.1.5 Mometasone .................................................................................................................... 73 14.1.6 Ibuprofen......................................................................................................................... 77 14.1.7 Oxedrine.......................................................................................................................... 79 14.1.8 Hyoscine Butylbromide .................................................................................................... 82 14.1.9 Iodine .............................................................................................................................. 82 14.2 SUSDP, PART 5.................................................................................................................... 84 14.2.1 Appendix H...................................................................................................................... 84 15. MATTERS REFERRED BY THE AUSTRALIAN DRUG EVALUATION COMMITTEE (ADEC) ................................................................................................................................................. 84 15.1 NEW SUBSTANCES........................................................................................................... 84 15.1.1 Riluzole ........................................................................................................................... 84 15.1.2 Ertapenem....................................................................................................................... 84 15.1.3 Valganciclovir ................................................................................................................. 84 15.1.4 Tenofovir......................................................................................................................... 85 15.1.5 Parecoxib
Load more

Recommended publications
  • NEEM: the Divine Tree, Azadirachta Indica
    NEEM Copyright © 1999 OPA (Overseas Publishers Association) N.V. Published by license under the Harwood Academic Publishers imprint, part of The Gordon and Breach Publishing Group. Medicinal and Aromatic Plants—Industrial Profiles Individual volumes in this series provide both industry and academia with in-depth coverage of one major medicinal or aromatic plant of industrial importance. Edited by Dr Roland Hardman Volume 1 Valerian edited by Peter J.Houghton Volume 2 Perilla edited by He-Ci Yu, Kenichi Kosuna and Megumi Haga Volume 3 Poppy edited by Jeno Bernáth Volume 4 Cannabis edited by David T.Brown Volume 5 Neem H.S.Puri Other volumes in preparation Allium, edited by K.Chan Artemisia, edited by C.Wright Basil, edited by R.Hiltunen and Y.Holm Caraway, edited by É. Németh Cardamom, edited by PN.Ravindran and KJ.Madusoodanan Chamomile, edited by R.Franke and H.Schilcher Cinnamon and Cassia, edited by P.N.Ravindran and S.Ravindran Colchicum, edited by V.Simánek Curcuma, edited by B.A.Nagasampagi and A.P.Purohit Ergot, edited by V.Kren and L.Cvak Eucalyptus, edited by J.Coppen Ginkgo, edited by T.van Beek Ginseng, by W.Court Hypericum, edited by K.Berger Buter and B.Buter Illicium and Pimpinella, edited by M.Miró Jodral Kava, edited by Y.N.Singh Licorice, by L.E.Craker, L.Kapoor and N.Mamedov Piper Nigrum, edited by P.N.Ravindran Plantago, edited by C.Andary and S.Nishibe Please see the back of this book for other volumes in preparation in Medicinal and Aromatic Plants—Industrial Profiles Copyright © 1999 OPA (Overseas Publishers Association) N.V.
    [Show full text]
  • NDPSC Record of Reasons, Meeting 37, Feb 2003
    National Drugs and Poisons Schedule Committee Record of the Reasons 37th Meeting 25-26 February 2003 The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information. National Drugs and Poisons Schedule Committee Record of the Reasons Meeting 37 - February 2003 i TABLE OF CON TEN TS GLOSSARY.........................................................................................................................IV 2. PROPOSED CHANGES/ADDITIONS TO PARTS 1 TO 3 AND PART 5 OF THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS. ........................9 2.1 SUSDP, PART 1 ..........................................................................................................9 2.2 SUSDP, PART 2 ..........................................................................................................9 2.3 SUSDP, PART 3 ..........................................................................................................9 2.3.1 Organotin Compounds...........................................................................................9 2.4.1 BORON TRIFLUORIDE, BIFLUORIDES AND HYDROSILICOFLUORIC ACID – APPENDIX F PART 3 ...9 AGRICULTURAL/VETERINARY, INDUSTRIAL AND DOMESTIC CHEMICALS.................. 11 3. MATTERS ARISING FROM THE MINUTES OF THE PREVIOUS MEETING (CONSIDERATION OF POST-MEETING SUBMISSIONS UNDER 42ZCZ).............................
    [Show full text]
  • Review on Herbal Teas
    Chandini Ravikumar /J. Pharm. Sci. & Res. Vol. 6(5), 2014, 236-238 Review on Herbal Teas Chandini Ravikumar BDS Student, Savitha Dental College, Chennai Abstract: Herbal tea is essentially an herbal mixture made from leaves, seeds and/ or roots of various plants. As per popular misconception, they are not derived from the usual tea plants, but rather from what are called as ‘tisanes’. There are several kinds of tisanes (herbal teas) that have been used for their medicinal properties. Some of them being consumed for its energizing properties to help induce relaxation, to curb stomach or digestive problems and also strengthen the immune system. Some of the popular herbal teas are Black tea, Green tea, Chamomile tea, Ginger tea, Ginseng tea, Peppermint tea, Cinnamon tea etc. Some of these herbal teas possess extremely strong medicinal benefits such as, Astragalus tea, a Chinese native herb that is used for its anti-inflammatory and anti-bacterial properties; which in many cases helps people living with HIV and AIDS. Demonstrating very few demerits, researchers continue to examine and vouch for the health benefits of drinking herbal teas. Key words:Camellia Sinensis, tisanes, types, medical benefits, ability to cure various ailments, advantages, disadvantages. INTRODUCTION: Herbal tea, according to many, look like tea and is brewed as the same way as tea, but in reality it is not considered a tea at all. This is due to the fact that they do not originate from the Camellia Sinensis bush, the plant from which all teas are made [1]. Herbal teas are actually mixtures of several ingredients, and are more accurately known as‘tisanes.’ Tisanes are made from combinations of dried leaves, seeds, grasses, nuts, barks, fruits, flowers, or other botanical elements that give them their taste and provide Image 1: Green tea the benefits of herbal teas [2].
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Medication: Duloxetine (Cymbalta) 30 Mg
    Duloxetine (Cymbalta) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Duloxetine (Cymbalta) 30 mg What is Duloxetine: Duloxetine is a type of medication called “Serotonin Norepinephrine Reuptake Inhibitors” or “SNRIs” that was initially developed to treat depression. It works by altering the levels of certain transmitters in the brain such as noradrenalin and serotonin. Duloxetine can also be used in the treatment of anxiety, irritable bowel syndrome (with constipation), pain, and certain symptoms of myalgic encephalomyelitis / chronic fatigue syndrome (but not the fatigue itself). Expected Benefit: Usually takes 4 – 6 weeks to notice a benefit What to expect: “Transition” effects o These symptoms are the effects of your body getting used to the medication (i.e., transition onto the medication) o It’s different for everybody. Some people feel “not like themselves,” a bit anxious, or unusual. o These symptoms typically go away after 7 to 10 days o Please call the CCDP if the anxiety is intolerable. Watch for possible side effects: This list of side effects is important for you to be aware of however, it is also important to remember that not all side effects happen to everyone. If you have problems with these side effects talk with your doctor or pharmacist: Trouble sleeping that is more than usual Heart burn, stomach upset Sexual dysfunction High blood pressure (Make sure you family doctor is regularly checking your blood pressure) Stopping the medication: This medication should not be stopped abruptly. Your doctor may advise you to reduce the dose slowly to help prevent your symptoms from returning.
    [Show full text]
  • Chamomile: a Herbal Medicine of the Past with a Bright Future (Review)
    MOLECULAR MEDICINE REPORTS 3: 895-901, 2010 Chamomile: A herbal medicine of the past with a bright future (Review) JANMEJAI K. SRIVASTAVA1,2,4, ESWAR SHANKAR1,2 and SANJAY GUPTA1-3 Department of Urology and Nutrition, 1Case Western Reserve University; 2University Hospitals Case Medical Center; 3Case Comprehensive Cancer Center, Cleveland, OH 44106, USA Received August 4, 2010; Accepted August 30, 2010 DOI: 10.3892/mmr.2010.377 Abstract. Chamomile is one of the most ancient medicinal Contents herbs known to mankind. It is a member of the Asteraceae/ Compositae family and is represented by two common 1. Introduction varieties, German Chamomile (Chamomilla recutita) 2. Bioactive constituents of chamomile and Roman Chamomile (Chamaemelum nobile). The 3. Healthcare preparations with chamomile dried flowers of chamomile contain many terpenoids 4. Traditional uses of chamomile and flavonoids, which contribute to its medicinal properties. 5. Scientific evaluation of chamomile Chamomile preparations are commonly used for many 6. Contraindications and safety issues with chamomile human ailments, including hay fever, inflammation, muscle 7. Conclusions spasms, menstrual disorders, insomnia, ulcers, wounds, gastrointestinal disorders, rheumatic pain and hemorrhoids. Essential oils of chamomile are used extensively in cosmetics 1. Introduction and aromatherapy. Numerous preparations of chamomile have been developed, the most popular being in the form of The effect of plants on human health has been documented herbal tea, of which more than one million cups are consumed for thousands of years (1-3). Herbs have been integral to both every day. In this review, we describe the use of chamomile traditional and non-traditional forms of medicine dating back in traditional medicine with regard to evaluating its curative at least 5000 years (2,4-6).
    [Show full text]
  • Understanding Herbal Formulas.Pptx
    9/18/14 Why Herbal Formulas? Understanding Herbal Formulas Steven Horne, RH(AHG) Rifle or Shotgun? Herbal Recipes • Like creang a single dish from Single Herbs Herbal Formulas a recipe of ingredients, an • Have deep and subtle • Subtle acGons tend to herbal formula is more than the acGons, affecGng mulGple balance out, creang a sum of the single acGons of its ingredients systems and processes more generalized acGon • Herbs can both enhance and • When matched correctly to • Have a more generalized neutralize the effects of other a person’s symptoms have acGon that affects the body herbs, so the blend is different powerful targeted acGon in a more diverse way (like a than the sum of its parts (like a rifle) shotgun) • People unskilled in herbalism oQen create “kitchen sink” • Require a lot of knowledge • Require less knowledge and formulas where they simply and skill to use effecGvely skill to use effecGvely blend together everything that has been historically used for a problem thinking that will fix everything Herbal EnergeGcs Herbs and Body Systems • Herbs have “energeGc” properGes that move • Herbs have affinity for various body systems and funcGons the body’s energies in certain direcGons, as • Formulas can be blended to support specific body systems in both structure and funcGon, such as: follows: – DigesGve formulas – Energy ProducGon: Herbs can warm (speed up – Respiratory formulas metabolism) or cool (slow down metabolism) – Urinary formulas – Minerals and Fluids: Herbs can moisten ssues or – Nervous system dry ssues formulas – Tissue Tone:
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Combining Herbs and Essential Oils This Presentation Explores How
    Hawthorn University Holistic Health and Nutrition Webinar Series 2017 www.hawthornuniversity.org Presented by David Crow, L.Ac. Combining Herbs and Essential Oils This presentation explores how essential oils and aromatherapy can be integrated with herbal treatments for added therapeutic effects and benefits. It explores which essential oils can be safely combined, and how, with herbs according to therapeutic functions: ) Expectorant, mucolytic, decongestant and antitussive herbs ) Nervine relaxant, sedative and anxiolytic herbs ) Demulcent herbs ) Anti-spasmotic and analgesic herbs ) Antimicrobial herbs ) Cholagogue and laxative herbs ) Immune modulating and immune stimulating herbs ) Adaptogen, trophorestorative and neuroendocrine regulating herbs ) Antiinflammatory herbs ) Emmenagogue and uterine tonic herbs Learning Objectives: ) When and how essential oils and aromatherapy are a primary, adjunct or contraindicated treatment ) To understand the compatibility or lack of compatibility of specific groups and species of essential oils and specific groups and species of herbs ) Simple combinations of herbs and essential oils for specific therapeutic benefits Introduction ) General suggestions for how to use safely therapeutic groups of essential oils in combinations with groups of herbs. ) Does not give detailed methods of use of the oils. ) Does not give any specific dosages or uses of herbs. ) Please do not use herbs without studying them in detail. ) Please use essential oils according to safe methods of applications ) Do not take internally ) Do not apply undiluted to the skin Difficulties classifying essential oils into therapeutic categories Where do the claims about therapeutic actions of essential oils come from? 1. Empirical evidence from long history of use of aromatic plants 2. Modern scientific studies 3. Claims made about essential oils through MLM companies and spread on the internet Many claims about the functions of essential oils are not substantiated or established.
    [Show full text]
  • Yeast, Fenugreek Seeds and Chamomile Flowers) on Some Behavioral Patterns and Productive Performance in Pigeons (Columba Livia Domestica) Eman H
    Benha Veterinary Medical Journal 39 (2020) 22-27 Benha Veterinary Medical Journal Official Journal Issued by Journal homepage: https://bvmj.journals.ekb.eg/ Faculty of Veterinary Medicine Since 1990 Original Paper Effect of some feed additives (yeast, fenugreek seeds and chamomile flowers) on some behavioral patterns and productive performance in pigeons (Columba livia domestica) Eman H. EL-Ghamry1, Mohamed M. Karousa1, Gaffar. M. EL-Gendi2, Essam A.Ali1 1Department of Veterinary Hygiene and Management, Faculty of Veterinary Medicine, Benha University. Egypt. 2Animal production department, faculty of Agriculture, Benha University. Egypt ARTICLE INFO ABSTRACT Keywords This work was carried out at the poultry farm-Animal production belonging to faculty of agriculture, Benha university through the period from April to the end of September 2019 to Behavior study the effect of some feed additives (Yeast, Fenugreek seeds and Chamomile flowers) on Feed additives some behaviors and productive performance of parent pigeons using 16 pairs of hybrid Pigeons pigeons (Carrier × local Egyptian Baladi) with age of 6 months, they were distributed according to their mating system (sex ratio 1:1). Pigeons were divided into 4 treatments each Productive performance. of them composed of 4 pairs and were reared under the same managerial conditions. The Reproductive obtained results revealed that pigeons fed on Yeast had high frequency of feeding, drinking Received 20/07/2020 and sitting on eggs also, it increased length of incubation period while, decreased hatchability Accepted 29/07/2020 %. Fenugreek seeds had high frequency of preening and sitting on eggs but, it decreased the Available On-Line length of incubation period.
    [Show full text]
  • Glycyrrhiza Glabra) Herb As a Feed Additive in Poultry: Current Knowledge and Prospects
    animals Review Use of Licorice (Glycyrrhiza glabra) Herb as a Feed Additive in Poultry: Current Knowledge and Prospects Mahmoud Alagawany 1,* , Shaaban S. Elnesr 2 , Mayada R. Farag 3, Mohamed E. Abd El-Hack 1 , Asmaa F. Khafaga 4, Ayman E. Taha 5, Ruchi Tiwari 6, Mohd. Iqbal Yatoo 7 , Prakash Bhatt 8, Gopi Marappan 9 and Kuldeep Dhama 10,* 1 Department of Poultry, Faculty of Agriculture, Zagazig University, Zagazig 44511, Egypt 2 Department of Poultry Production, Faculty of Agriculture, Fayoum University, Fayoum 63514, Egypt 3 Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt 4 Department of Pathology, Faculty of Veterinary Medicine, Alexandria University, Edfina 22758, Egypt 5 Department of Animal Husbandry and Animal Wealth Development, Faculty of Veterinary Medicine, Alexandria University, Edfina 22758, Egypt 6 Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU), Mathura-281001, Uttar Pradesh, India 7 Division of Veterinary Clinical Complex, Faculty of Veterinary Sciences and Animal Husbandry, Jammu and Kashmir, Srinagar 190006, India 8 Teaching Veterinary Clinical Complex, College of Veterinary and Animal Sciences, Govind Ballabh Pant University of Agriculture and Technology, Pantnagar-263145 (Udham Singh Nagar), Uttarakhand, India 9 Division of Avian Physiology and Reproduction, ICAR-Central Avian Research Institute, Izatnagar,
    [Show full text]
  • The Dynamics of Technological Innovation: the Case of the Pharmaceutical Industry
    Research Policy 30Ž. 2001 535–588 www.elsevier.nlrlocatereconbase The dynamics of technological innovation: the case of the pharmaceutical industry Basil Achilladelis a,), Nicholas Antonakis b a 39, Ionias Street, Kifissia, Athens 14563, Greece b Ministry of DeÕelopment and UniÕersity of Athens, Athens Greece Received 9 April 1999; received in revised form 7 October 1999; accepted 18 January 2000 Abstract This is an empirical and historical study of the dynamics of technological innovationŽ. TI in the pharmaceutical industry from its establishment at the beginning of the 19th century to 1990. It is based on the identification and evaluation of the originality and commercial significance of 1736 product innovationsŽ. new medicines commercialized between 1800 and 1990, and on company economic data for the period 1950–1990. The study is presented in the framework of established macroeconomic theory of technical change. Applying both empirical and historical evidence, the study:Ž. a identifies the technological, social and economic driving forces for TI;Ž. b examines the relation between originality and market performance of medicinal innovations;Ž. c studies the mechanisms of the diffusion of medicinal technologies that led to the formation of five successive generations of drugsŽ long waves.Ž. ; d describes the structural changes forced on the pharmaceutical industry by the introduction and development of each successive generation of drugs;Ž. e provides evidence of the concentration of the innovative segment of the pharmaceutical industry among few large companies, which sustained high levels of growth and R&D expenditures by means of inhouse innovation, technological and therapeutic market specialization, and mergers and acquisitions of companies within and outside the pharmaceutical industry; andŽ.
    [Show full text]